28.04.2016 18:40:00
|
AbbVie Inc. -- Moody's reviews AbbVie's Baa1 for downgrade
New York, April 28, 2016 -- Moody's Investors Service placed the Baa1 senior unsecured long-term ratings of AbbVie Inc. ("AbbVie") under review for downgrade. At the same time, Moody's affirmed AbbVie's Prime-2 commercial paper rating. This action follows the announcement that AbbVie will acquire privately-held Stemcentrx for approximately $5.8 billion in cash and stock.